EDIT

Editas Medicine (EDIT)

About Editas Medicine (EDIT)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Details

Daily high

$3.25

Daily low

$3.10

Price at open

$3.17

52 Week High

$11.69

52 Week Low

$2.91

Market cap

267.2M

Dividend yield

0.00%

Volume

1.5M

Avg. volume

2.3M

P/E ratio

-1.37

Editas Medicine News